Catalent Micron Technologies - Enhanced bioavailability
Catalent provides end-to-end solutions to accelerate drug development programmes and with the addition of Micron Technologies’ particle size engineering capabilities, now has the broadest bioavailability solutions toolkit in the industry.
Catalent Micron Technologies - Enhanced bioavailability.Proven Results.
With the addition of Micron Technologies’ particle-size engineering expertise and experience, Catalent can support clients at the earliest stages of the drug development process, and provide end-to-end solutions to accelerate programmes to the clinic and market with the broadest bioavailability solutions toolkit in the industry. Micronization has many benefits, and is typically the first choice technology to improve the solubility performance of the product:
- Proven history
- Versatility (works on wide range of compounds)
- Broad acceptance (well understood by regulatory authorities)
- Scalable process
- Maximum efficiency (consistently produces high yields)
- Heat-free process (reduces risk of degradation)
Catalent Micron Technologies is the leading global provider for the most complex, specialised requirements in micronization, with the expertise to handle your toughest specifications. Micronization is used across most solid oral dosage types and inhalation delivery technologies to address increasing drug performance challenges.
Capabilities in particle size engineering include:
- Micronization
- Mechanical milling
- Cryogenic milling
- Highly potent and cytotoxic compounds
- Comprehensive analytical services
more products. better treatments. reliably supplied.™
Clinical Supply Planning in Europe - Balancing Cost, Flexibility and Time
December 19th 2024The packaging and distribution of clinical supplies is a fundamental piece to the overall success of a clinical trial, and advance preparation can help establish a more efficient supply chain. Selecting the best geographical location for those activities, however, depends on the clinical trial protocol, business decisions, and even the investigational medicinal product (IMP) being studied.
